The approval of the first CRISPR-based therapy in late 2023—CRISPR Therapeutics and Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel or exa-cel) for sickle cell disease and β ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

The FDA has started a priority review of Vertex Pharma and CRISPR Therapeutics’ exagamglogene autotemcel (exa-cel) in sickle cell disease (SCD), with a decision on approval due by 8th December.

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP), a pioneer in gene-based medicine, has announced that Chief Operating Officer Julianne Bruno is set to leave the company on April 11, ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP), a pioneer in gene-based medicine, has announced that Chief Operating Officer Julianne Bruno is set to leave the company on April 11 ...